Stroke

Cardiovascular departments are playing a role in stroke interventions at numerous health systems, working as part of the stroke care team with neurologists, radiology and the emergency department. Stroke first has be be classified as ischemic or hemorrhagic. These have very different care pathways. Ischemic strokes are increasingly being treated with neurological-interventional therapy that includes catheter based mechanical thrombectomy to remove the clot. This is a more aggressive treatment compared to traditional IV administration of tissue plasminogen activator (tPA) thrombolytic therapy to dissolve the clot. Subarachnoid hemorrhage (SAH) and  intracerebral hemorrhage (ICH) brain bleeds can also be treated in some cases stent flow diverters and embolization coils. 

RSS icon
homeless teenager

Food insecurity increases risk of poor heart health in young adults

Food insecurity—lacking consistent access to the food needed to live an “active, healthy lifestyle”—impacts up to one in eight Americans each year. 

IV hospital room intravenous drip solution

Tenecteplase compares favorably to alteplase in new comparison of FDA-approved stroke drugs

Researchers explored data from nearly 80,000 patients, comparing the newest clot-busting stroke drug from Genetech with its predecessor.

Nicholas Galante

AI is revolutionizing radiology workflow and patient care

Sponsored by Viz.ai

In the rapidly evolving healthcare landscape, artificial intelligence (AI) is making significant strides in improving radiology workflow and patient care coordination. Nicholas Galante, MD, medical director of informatics at Radiology Associates of North Texas, recently discussed how technology from Viz.ai is transforming his radiology practice, enhancing efficiency, and ultimately benefiting patient outcomes. 

Thumbnail

FDA approves first new clot-dissolving drug for ischemic stroke in decades

Tenecteplase is a tissue plasminogen activator given to patients through a single five-second intravenous bolus. It is only the second drug of its kind to gain FDA approval, and the first in many years.

The late-breaking U.S. multicenter admIRE clinical trial at the Heart Rhythm Society 2024 meeting, showed positive data on the long-term safety and effectiveness of the the Biosense Webster Varipulse pulsed field ablation (PFA) system in patients with paroxysmal atrial fibrillation. #HRS #HRS2024 #PFA

FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.

Aakriti Gupta, MD, Cedars-Sinai, explains use of cerebral embolic protection devices in TAVR

An updated look at the use of cerebral embolic protection devices during TAVR

Cardiologist Aakriti Gupta, MD, MSc, spoke to Cardiovascular Business about the latest data and trends associated with using cerebral embolic protection devices during TAVR to lower the risk of stroke.

heart drugs with stethoscope

Sotagliflozin the first drug of its kind to limit heart attacks, strokes in high-risk patients

Sotagliflozin, a dual SGLTI and SGLT2 inhibitor, can significantly reduce the risk of adverse cardiovascular events in patients with type 2 diabetes, CKD and additional cardiovascular risk factors, according to a new study of more than 10,000 patients. 

Johnson & Johnson MedTech has launched a new next-generation catheter to be used when treating acute ischemic stroke patients. The Cereglide 92 Catheter System includes a 0.92” catheter as well as the company’s Innerglide 9 deliver aid.

Johnson & Johnson MedTech launches new large-bore catheter system for stroke

The next-generation catheter was designed to help clinicians restore blood flow safely and effectively after patients have experienced an acute ischemic stroke. 

Displaying 25 - 32 of 121
Design by Adaptive Theme